SPYRE THERAPEUTICS, INC. Net Change in Cash
SPYRE THERAPEUTICS, INC. (SYRE) reported Net Change in Cash of $76.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $11.46M.
- SPYRE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$40.93M, a 205.88% decline year-over-year.
- SPYRE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $38.66M, a 28116.06% increase year-over-year.
- SPYRE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $137.00K.
- SPYRE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$3.70M.
- SPYRE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$99.79M, a 165.31% decline from fiscal 2023.
- SPYRE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $152.80M, a 686.16% increase from fiscal 2022.
- SPYRE THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $19.44M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $76.29M 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $11.46M 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | -$3.70M 10-K · filed 2026-02-19 | |||
| 2025-09-30 | -$24.53M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | -$7.76M 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | -$40.93M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | -$99.79M 10-K · filed 2026-02-19 | |||
| 2024-09-30 | -$117.64M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | -$143.75M 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | $38.66M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $152.80M 10-K · filed 2026-02-19 | |||
| 2023-09-30 | $55.48M 10-Q/A · filed 2024-11-18 | |||
| 2023-06-30 | $200.26M 10-Q/A · filed 2024-11-18 | |||
| 2023-03-31 | $137.00K 10-Q/A · filed 2024-11-18 | |||
| 2022-12-31 | $19.44M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $23.54M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $22.29M 10-Q · filed 2023-08-11 | |||
| 2022-03-31 | -$515.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$74.96M 10-K/A · filed 2024-11-18 | |||
| 2021-09-30 | -$65.44M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | -$55.33M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | -$9.86M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $71.18M 10-K · filed 2023-03-02 | |||
| 2020-09-30 | $34.97M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $46.46M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | -$6.66M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | -$1.71M 10-K · filed 2022-03-08 | |||
| 2019-09-30 | $3.58M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $4.47M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $63.18M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $9.64M 10-K · filed 2021-03-18 | |||
| 2018-09-30 | $1.72M 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | $7.76M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | -$2.06M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | -$34.93M 10-K · filed 2020-02-24 | |||
| 2017-09-30 | -$34.59M 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | $18.45M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |